Jiangxi Fuxiang Pharmaceuticals won 500 million anti-thrombosis drugs and Zhengda Qinglong and other "fire fight" the original research drug

Pharmaceutical Network July 7th, July 6, Fuxiang Pharmaceutical Co., Ltd(Jiangxi Fuxiang Pharmaceutical Co., Ltd.) announced that its controlling subsidiary has been approved by the State Drug Administration issued a "drug registration approval." According to Minnet.com, sales of Agaquban injections at the end of China's public medical institutions in 2019 exceeded 500 million yuandrugdata show that Agaquban is an anticoagulant drug in the cardiovascular field, is a synthetic argine derivative, can inhibit the activity of coagulation enzyme, thus producing anticoagulant effect, with fast effect, short action time, low bleeding tendency, no immunogenicity and other advantagesDeveloped by Japan's Tianbian Mitsubishi, the drug was approved for sale in Japan in January 1990 and includes acute cerebral thrombosis, hemodialysis for people with anticoagulase deficiency, and heparin-induced thrombocytopenia (HIT)In June 2000, it was approved for anti-thrombotic therapy for heparin-induced platelet reduction in adultsIn the European Union, Agaquban has also been approved for interventional treatment of the epithelial coronary artery in HIT patientsIn recent years, china's public medical institutions terminal AgaQuban injection sales (units: 10,000 yuan)-meter net data show that in 2019 China's urban publichospitals
county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal Agaquban injection sales of more than 500 million yuan, in recent years, the growth rate of more than 15%Before, the domestic productionenterprisesTianjin Pharmaceutical Research Institute, Shandong New Era Pharmaceuticals, Nanjing Zhengda Tianqing Pharmaceuticals, Hunan Cylon Pharmaceuticals and other 6Fuxiang Pharmaceuticals said that the acquisition of the Agaquban injection ofdrug registrationbatch, marking the company's consolidation and upgrading of the existing industrial chain on the basis of the expansion of anticoagulant drugs in the cardiovascular field, further realized the extension to the field of downstream preparations, to achieve the "intermediate - API - preparation integration" development strategy, enhance the company's core competitivenessMinnet White Feather finishingSource: Minnet Net Database, Announcement